Olanzapine and peripheral metabolic dysregulation: organ-resolved mechanisms, risk, and MASLD-aligned care pathways

Shuwei Weng, Jinjxiu Lin, Dajun Chai · 2026

Read Olanzapine and peripheral metabolic dysregulation: organ-resolved mechanisms, risk, and MASLD-aligned care pathways by Shuwei Weng, Jinjxiu Lin, Dajun Chai (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13082975.txt.

Description

Shuwei Weng and co-authors map how a mind drug harms body fuel use in a 2025 review, per its head. Olanzapine treats grave mind illness, but oft brings weight gain and blood sugar harm. Past views blamed the brain, yet harm spreads through many organs.

The review tracks harm in liver, fat, muscle, pancreas, and gut in turn. Fat handling in the liver slips, brown fat heat dims, and sugar cells strain and fail. Risk shifts with age, genes, smoke, and dose length. A care path with early checks, liver scans, and set drug aids is laid out for clinics.

Catalog record

CREATORShuwei Weng, Jinjxiu Lin, Dajun Chai
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13082975

Browse the full library · About the Tower of Babel